‹ ›
MYP_006414
← PREVIOUS NEXT → BACK
Basic Information
Peptide Ctry2459 (H3)
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-Hepatitis virus ▸ Anti-HCV
Antiviral ▸ Virucidal activity
Enzyme modulation ▸ Enzyme inhibition ▸ Infection inhibition
Toxicity / Safety ▸ Blood cell toxicity ▸ Hemolysis ▸ Hemolytic
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Toxic
Venom / Toxin ▸ General toxin ▸ Toxicity
Standard
9 amino acids
C63H83N15O10
Standard
Sequence
FLHFLHHLF
Physicochemical Analysis
1210.43 Da
7.02
0.02
-0.33
0.0024
1.13
0.54
0.62
-2.63
130.00
0.3333
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
382.16
2.04
13.0
13.0
35.0
88.0
6.0
8.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0271041 VERIFIED: YES
Provenance & Taxonomy
Synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Amidation
Bio-Activity Profile
Antimicrobial Antiviral Cytotoxic
PaperDesign of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus. Biomaterials. 2013 Feb 13;34(13):3511-3522. doi: 10.1016/j.biomaterials.2013.01.075. PMID: 23415044. PMID23415044 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/23415044/
RECORD: Rec_0347352 VERIFIED: YES
Provenance & Taxonomy
Synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Amidation
Bio-Activity Profile
Antimicrobial Antiviral
cells
500 μg/mL
CC50
PaperDesign of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus. Biomaterials. 2013 Feb 13;34(13):3511-3522. doi: 10.1016/j.biomaterials.2013.01.075. PMID: 23415044. PMID23415044 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/23415044/
RECORD: Rec_0351060 VERIFIED: YES
Provenance & Taxonomy
Synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Amidation
Bio-Activity Profile
Antimicrobial Antiviral
Virus: Hepatitis C virus
0.85 μg/mL
EC50
PaperDesign of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus. Biomaterials. 2013 Feb 13;34(13):3511-3522. doi: 10.1016/j.biomaterials.2013.01.075. PMID: 23415044. PMID23415044 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/23415044/
RECORD: Rec_0386963 VERIFIED: YES
Provenance & Taxonomy
Synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
infection
0.85 μg/mL
EC50
PaperDesign of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus.
RECORD: Rec_0412417 VERIFIED: YES
Provenance & Taxonomy
Synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Amidation
Bio-Activity Profile
Antimicrobial Antiviral Hemolytic
PaperDesign of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus. Biomaterials. 2013 Feb 13;34(13):3511-3522. doi: 10.1016/j.biomaterials.2013.01.075. PMID: 23415044. PMID23415044 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/23415044/
FIRST PREV 1 2 3 4 NEXT LAST
Showing 5 records on this page · Page 3 of 4